Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies

• Published in: The Journal of asthma 2023-02, Vol.60 (2), p.403-411
• Main Authors: Sagara, Hironori, D'Andrea, Peter, Tanase, Ana-Maria, Pethe, Abhijit, Tanaka, Yukina, Matsuo, Kazutaka, Hosoe, Motoi, Nakamura, Yoichi
• Format: Article
• Language: English
• Subjects: Acetates - therapeutic use; Administration, Inhalation; adrenergic agonist/inhaled corticosteroid (LABA/ICS); adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid (LABA/LAMA/ICS); Adrenergic beta-2 Receptor Agonists - therapeutic use; Adult; Asthma - drug therapy; Asthma control; Bronchodilator Agents - therapeutic use; Drug Combinations; East Asian People; Glycopyrrolate - therapeutic use; Humans; Japan; long-acting β; lung function; Mometasone Furoate - therapeutic use; safety; Treatment Outcome
• ISSN: 0277-0903; 1532-4303
• DOI: 10.1080/02770903.2022.2056048

The 52-week long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) high-dose (150/50/160 µg) and IND/MF high-dose (150/320 µg) was evaluated in two studies enrolling Japanese patients with inadequately controlled asthma. Study 1 (IND/GLY/MF) and Study 2 (IND/MF) were 52-week, phase III, open-label, single-arm, multicenter studies conducted in Japanese adult patients with inadequately controlled asthma. The primary endpoint was incidence and severity of treatment-emergent adverse events (AEs) over 52-weeks. In Study 1, 94 patients received IND/GLY/MF high-dose and 84 (89.4%) patients completed the 52-week study treatment; in Study 2, 51 patients received IND/MF high-dose and 48 (94.1%) patients completed the 52-week study treatment. In Study 1, 68.1% and 6.4% of 94 patients reported ≥1 AE and ≥1 serious AE (SAE) respectively. In Study 2, 78.4% of 51 patients reported ≥1 AE; no patients reported SAEs. The most commonly reported AEs were asthma (exacerbation; 30.9% and 54.9%) and nasopharyngitis (18.1% and 29.4%) in Study 1 and Study 2, respectively. Severe AEs including asthma (exacerbation) were reported in 13.8% and 13.7% of patients in Study 1 and Study 2, respectively. In Study 1, 10 patients (10.6%) reported treatment-related AEs, of which dysphonia (9 patients [9.6%]) was the most commonly reported; no treatment-related AEs were reported in Study 2. In Study 1, one death (not study drug-related) was reported after study discontinuation (92 days after last dose of study medication). Once-daily IND/GLY/MF and IND/MF high-dose were well-tolerated in Japanese patients with inadequately controlled asthma. No unexpected safety findings were observed. Supplemental data for this article is available online at